$RAFFLES M_老虎社区_美港股上老虎

weekeepeedia
2021-10-25

Good time to accumulate?

CLSA downgrade. We turn more cautious on Raffles Medical (RFMD) following a policy change regarding PCR testing for passengers arriving to Changi Airport. From 27 Oct, passengers from a number of countries (Category 2 to 4) will no longer need to undergo PCR tests upon arrival. Although the vaccinated travel lane (VTL) still requires PCR tests and could drive 2022 earnings, its share is unlikely to enjoy a further rerating, in our view. Risk of further policy changes regarding PCR tests/prices, coupled with its earnings reliance on PCR tests could weigh on the stock. We cut our 2022-2023 estimates by 4%-8%, downgrade our recommendation from BUY to Underperform and lower our target price from S$1.87 to S$1.60 based on a c.18x 22CL EV/Ebitd

# 新交所交易提示

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":856048780,"tweetId":"856048780","gmtCreate":1635134160169,"gmtModify":1635137298049,"author":{"id":3553153005910044,"authorId":3553153005910044,"authorIdStr":"3553153005910044","name":"weekeepeedia","avatar":"https://static.tigerbbs.com/2776cd1108df916ffd79367b2b25fea9","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":11,"starInvestorFlag":false},"themes":[{"themeId":"9f2bf15c08d148e0811776798953eeda","categoryId":"b76d3c59fc044df59779c041b25852a6","name":"新交所交易提示","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":9f2bf15c08d148e0811776798953eeda}&rnconfig={\"headerBarHidden\": true}","description":"对投资SGX有什么想法和经验吗？分享给这里所有的老虎吧！","image":"https://static.tigerbbs.com/76e613d82ca018b2d02881597b5f4667"}],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><a href=\"https://laohu8.com/S/BSL.SI\">$RAFFLES MEDICAL GROUP LTD(BSL.SI)$</a>Good time to accumulate?CLSA downgrade. We turn more cautious on Raffles Medical (RFMD) following a policy change regarding PCR testing for passengers arriving to Changi Airport. From 27 Oct, passengers from a number of countries (Category 2 to 4) will no longer need to undergo PCR tests upon arrival. Although the vaccinated travel lane (VTL) still requires PCR tests and could drive 2022 earnings, its share is unlikely to enjoy a further rerating, in our view. Risk of further policy changes regarding PCR tests/prices, coupled with its earnings reliance on PCR tests could weigh on the stock. We cut our 2022-2023 estimates by 4%-8%, downgrade our recommendation from BUY to Underperform and lower our target price from S$1.87 to S$1.60 based on a c.18x 22CL EV/Ebitd</body></html>","htmlText":"<html><head></head><body><a href=\"https://laohu8.com/S/BSL.SI\">$RAFFLES MEDICAL GROUP LTD(BSL.SI)$</a>Good time to accumulate?CLSA downgrade. We turn more cautious on Raffles Medical (RFMD) following a policy change regarding PCR testing for passengers arriving to Changi Airport. From 27 Oct, passengers from a number of countries (Category 2 to 4) will no longer need to undergo PCR tests upon arrival. Although the vaccinated travel lane (VTL) still requires PCR tests and could drive 2022 earnings, its share is unlikely to enjoy a further rerating, in our view. Risk of further policy changes regarding PCR tests/prices, coupled with its earnings reliance on PCR tests could weigh on the stock. We cut our 2022-2023 estimates by 4%-8%, downgrade our recommendation from BUY to Underperform and lower our target price from S$1.87 to S$1.60 based on a c.18x 22CL EV/Ebitd</body></html>","text":"$RAFFLES MEDICAL GROUP LTD(BSL.SI)$ Good time to accumulate? CLSA downgrade. We turn more cautious on Raffles Medical (RFMD) following a policy change regarding PCR testing for passengers arriving to Changi Airport. From 27 Oct, passengers from a number of countries (Category 2 to 4) will no longer need to undergo PCR tests upon arrival. Although the vaccinated travel lane (VTL) still requires PCR tests and could drive 2022 earnings, its share is unlikely to enjoy a further rerating, in our view. Risk of further policy changes regarding PCR tests/prices, coupled with its earnings reliance on PCR tests could weigh on the stock. We cut our 2022-2023 estimates by 4%-8%, downgrade our recommendation from BUY to Underperform and lower our target price from S$1.87 to S$1.60 based on a c.18x 22CL EV/Ebitd","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/856048780","repostId":0,"isVote":1,"tweetType":1,"viewCount":1054,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["BSL.SI"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":679,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

评论（1）

热议股票